4-甲基哌嗪-2-甲酸甲酯 | 56903-89-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-甲基哌嗪-2-甲酸甲酯
• 中文别名: 2-羧酸甲酯-4-甲基哌嗪；4-甲基-2-哌嗪羧酸甲酯
• 英文名称: 4-methylpiperazine-2-carboxylic acid methyl ester
• 英文别名: 4-methyl-piperazine-2-carboxylic acid methyl ester；3-Carbomethoxy-1-methyl-piperazin；Methyl 4-methylpiperazine-2-carboxylate
• CAS: 56903-89-0
• 化学式: C₇H₁₄N₂O₂
• mdl: MFCD12405921
• 分子量: 158.2
• InChiKey: IGLUXKFXZQJKBN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

SDS

Name:	4-Methylpiperazine-2-Carboxylic Acid Methyl Ester Material Safety Data Sheet
Synonym:	None Known
CAS:	56903-89-0

Section 1 - Chemical Product MSDS Name:4-Methylpiperazine-2-Carboxylic Acid Methyl Ester Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
56903-89-0	4-Methylpiperazine-2-Carboxylic Acid M	ca. 100	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea.
Inhalation:
Causes respiratory tract irritation. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 56903-89-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 75 deg C @ 760mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H14N2O2
Molecular Weight: 158.2

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 56903-89-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Methylpiperazine-2-Carboxylic Acid Methyl Ester - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 56903-89-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 56903-89-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 56903-89-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-甲基哌嗪-2-甲酸甲酯 在 lithium aluminium tetrahydride 、 铁粉 、 溶剂黄146 、 N,N-二异丙基乙胺 、 O,O'-dibenzoyl-L-tartaric acid 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 18.0h， 生成 (R)-(-)-2-methyl-1,2,3,4,5,10,11,11a-octahydro-2,4a,10-triazadibenzo[a,d]cycloheptene
  参考文献：
  名称：

  Synthesis, resolution, and absolute configuration of novel tricyclic benzodiazepines

  摘要：

  The synthesis, resolution, and stereochemical characterization of novel piperazino-, thiazino-, and oxazinoberizodiazepines are described. The absolute stereochemistry of the heterotricycles was determined by using X-ray crystallography and the enantiomeric purity was determined by using Pirkle-solvent NMR techniques and chiral HPLC. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2004.02.028
• 作为产物：
  描述：

  1-benzyl-4-methyl-piperazine-2-carboxylic acid methyl ester 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 反应 18.0h， 以92%的产率得到4-甲基哌嗪-2-甲酸甲酯
  参考文献：
  名称：

  具有中心烟碱作用的N1-乙酰基-N4-二甲基-哌嗪碘化物（ADMP）和N1-苯基-N4-二甲基-哌嗪碘化物（DMPP）的杂交和等距类似物。

  摘要：

  通过将N1-乙酰基-N4-二甲基哌嗪碘化物（1，ADMP）和N1-苯基-N4-二甲基哌嗪碘化物（3，DMPP）或相应的叔碱基（2， 4）用槟榔碱（5）和槟榔酮（6）或通过等规取代DMPP的苯环。杂交提供了既作为叔碱又作为碘甲基化物的化合物，其对烟碱样受体没有亲和力。相反，等位取代使化合物对受体保持亲和力。其中，两个叔碱基（37、38）对烟碱样受体具有纳摩尔级的亲和力。这些异构化合物的药理学特征非常有趣，因为它们的外周和中枢作用存在差异，

  DOI：

  10.1016/s0968-0896(98)00259-4

文献信息

• DERIVATIVES OF N-[(1H-PYRAZOL-1-YL)ARYL]-1H-INDOLE OR 1H-INDAZOLE-3-CARBOXAMIDE, PREPARATION THEREOF AND APPLICATIONS THEREOF IN THERAPEUTICS
  申请人：Badorc Alain

  公开号：US20120277205A1

  公开（公告）日：2012-11-01

  The present invention relates to compounds corresponding to formula (I): in which: A represents a divalent aromatic radical; X represents a —CH— group or a nitrogen atom; R 1 represents a (C 1 -C 4 )alkyl or a (C 1 -C 4 )alkoxy; R 2 represents a group Alk; R 3 represents a hydroxyl or a group —NR 7 R 8 ; R 4 represents a hydrogen atom, a halogen atom, a cyano, a phenyl, a group Alk, a group OAlk or a group —NR 9 R 10 ; R 5 represents a hydrogen atom, a halogen atom or a group Alk; R 6 represents a hydrogen atom, a halogen atom, a cyano, a group —COOAlk or a —CONH 2 group.

  该发明涉及与式(I)对应的化合物：其中：A代表二价芳香基团；X代表一个—CH—基团或一个氮原子；R1代表(C1-C4)烷基或(C1-C4)烷氧基；R2代表一个烷基基团；R3代表一个羟基或一个基团—NR7R8；R4代表氢原子、卤素原子、氰基、苯基、烷基基团、氧烷基团或基团—NR9R10；R5代表氢原子、卤素原子或一个烷基基团；R6代表氢原子、卤素原子、氰基、基团—COOAlk或基团—CONH2。
• [EN] USE OF INDOLYL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT ALLERGIC RHINITIS<br/>[FR] METHODE DE TRAITEMENT DE RHINITE ALLERGIQUE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2004022061A1

  公开（公告）日：2004-03-18

  A method to treat allergic rhinitis is disclosed in which patients are administered certain indolyl compounds.

  揭示了一种治疗过敏性鼻炎的方法，其中患者被施用特定的吲哚化合物。
• Heterocyclic compounds
  申请人：——

  公开号：US20030207893A1

  公开（公告）日：2003-11-06

  Heterocyclic compounds and methods of making them and using them.

  杂环化合物及其制备和使用方法。
• Method to treat allergic rhinitis
  申请人：——

  公开号：US20040132715A1

  公开（公告）日：2004-07-08

  A method to treat allergic rhinitis is disclosed in which patients are administered certain indolyl compounds.

  本发明揭示了一种治疗过敏性鼻炎的方法，其中患者被给予某些吲哚类化合物。
• Kinase inhibitors
  申请人：Chan Tin-Yau

  公开号：US20080004257A1

  公开（公告）日：2008-01-03

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease.

  具有公式（I）一般结构的化合物，或其药学上可接受的盐、溶剂或酯，可用于治疗免疫缺陷、癌症、心血管疾病、内分泌紊乱、帕金森病、代谢性疾病、肿瘤发生、阿尔茨海默病、心脏病、糖尿病、神经退行性疾病、炎症、肾脏疾病、动脉硬化和气道疾病等疾病、障碍或状况的治疗。